Physician profile
Anne Ward
NPI 1952858938
$3,815.63
in general payments reported to CMS, 2019-2025
27 companies · $741 in 2025
The $741 reported for 2025 was more than what 82% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $200 · 2022: $290 · 2023: $1,047 · 2024: $1,538 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,326.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $533.53 | 2021-2023 | Nuplazid |
| Alnylam Pharmaceuticals INC. | $330.27 | 2023-2025 | Amvuttra |
| Amgen INC. | $296.07 | 2023-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $270.33 | 2023-2025 | |
| Pfizer INC. | $255.51 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $227.42 | 2024 | Camzyos |
| Merck Sharp & Dohme LLC | $180.53 | 2023-2025 | Verquvo |
| Urovant Sciences INC | $176.08 | 2021-2022 | |
| Abbott Laboratories | $159.70 | 2023-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Gallant |
| Regeneron Healthcare Solutions, INC. | $145.70 | 2024 | Evkeeza |
| Silk Road Medical, INC. | $139.48 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Alexion Pharmaceuticals, INC. | $128.56 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $121.84 | 2024 | Austedo Xr |
| Eisai INC. | $121.45 | 2024 | |
| Edwards Lifesciences Corporation | $119.01 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $109.47 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $96.43 | 2023-2024 | Farxiga, Wainua |
| Idorsia Pharmaceuticals US INC | $96.40 | 2025 | Tryvio |
| Janssen Pharmaceuticals, INC | $83.78 | 2023-2024 | Xarelto |
| Esperion Therapeutics, INC. | $67.73 | 2024 | Nexletol |
| Bridgebio Pharma, INC. | $33.29 | 2025 | Attruby |
| Sun Pharmaceutical Industries INC. | $29.91 | 2021 | |
| Novo Nordisk INC | $25.00 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.40 | 2024 | Jardiance |
| Lilly USA, LLC | $15.87 | 2024 | Zepbound, Jardiance |
| Cvrx, INC. | $15.55 | 2023 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $15.32 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.